AVDL News and Press, Avadel Pharmaceuticals plc From 08/09/22

Avadel Pharmaceuticals plc (AVDL) Q2 2022 Earnings Conference Call August 09, 2022, 08:00 AM ET Company Participants Brandi Robinson - Senior Vice President of Corporate Affairs Gregory Divis - Chief Executive Officer Jennifer Gudeman - Vice President of Medical ...

Avadel Pharmaceuticals press release ( NASDAQ: AVDL ): Q2 GAAP EPS of -$1.07 misses by $0.66 . The workforce reduction will be completed during the third quarter of 2022 and the Company expects to reduce quarterly cash operating expenses, excluding inventory purchases,...

Received tentative approval for LUMRYZ™ (sodium oxybate) extended-release for oral suspension from FDA on July 18 Advancing key activities to potentially accelerate final approval and shorten launch window of LUMRYZ Extended cash runway to final FDA decision ...

Avadel Pharmaceuticals ( NASDAQ: AVDL ) is scheduled to announce Q2 earnings results on Monday, August 9th, before market open. The consensus EPS Estimate is -$0.40 (-21.2% Y/Y) and the consensus Revenue Estimate is $0M Over the last 3 months, EPS estimates have seen 3...

Major earnings expected before the bell on Tuesday include: Bausch Health Companies ( BHC ) Cronos Group ( CRON ) Emerson Electric ( EMR ) Norwegian Cruise Line Holdings ( NCLH ) Workhorse Group ( WKHS ) For further details see: Notable ea...

DUBLIN, Ireland, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that it will host a conference call and live webcast at 8:00 a.m. ET on Tuesday, August 9, 2022, to...

The U.S. Food and Drug Administration (FDA) granted tentative approval to Avadel Pharmaceuticals' ( NASDAQ: AVDL ) Lumryz to treat excessive daytime sleepiness (EDS) or cataplexy in adults with narcolepsy. The company said the final approval for Lumryz, also known a...

- Validates the safety profile and clinical efficacy of LUMRYZ - Pursuing strategies to accelerate final approval DUBLIN, Ireland, July 19, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transfor...

Gainers: Avadel Pharmaceuticals ( AVDL ) +5% . Cerence ( CRNC ) +4% . Tricida ( TCDA ) +3% . Plains All American Pipeline ( PAA ) +3% . Vir Biotechnology ( VIR ) +2% . Losers: Codexis ( CDXS ) -18% . 10x Genom...

Gainers: Rubicon Technology ( RBCN ) +68% . Faraday Future Intelligent Electric ( FFIE ) +65% . Ra Medical Systems ( RMED ) +61% . Xilio Therapeutics ( XLO ) +35% . Maris-Tech ( MTEK ) +35% . Lexicon Pharmaceuticals ( LXRX ...